January 10, 2017
A California judge Tuesday dismissed a decade-old action claiming Amgen Inc.'s board caused more than $1 billion in damages by overseeing an off-label drug marketing scheme, saying the shareholder failed to make a demand on the officials to instigate litigation before filing her suit.
January 09, 2017
Amgen Inc. told a California judge Monday that a decade-old action claiming the company's board caused more than $1 billion in damages by overseeing an off-label marketing scheme lacked facts to support "conclusory allegations" and should be tossed not "supplemented" as the shareholder plaintiffs suggested.
November 17, 2016
An Amgen Inc. shareholder told a California federal court Wednesday that she didn't need to make a demand for litigation before bringing her now-reopened, 9-year-old action against the company's officers and directors alleging they caused more than $1 billion in damages by overseeing an off-label marketing scheme.